5-Aminolaevulinic acid enhances ultrasound-induced mitochondrial damage in K562 cells

Yong He1, Xinshu Xia, Chuanshan Xu

  • 1Department of Rehabilitation Medicine, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Ultrasonics
|April 13, 2010
PubMed
Abstract

Insights

5-aminolaevulinic acid (5-ALA) significantly enhances ultrasound therapy's cancer cell killing ability. This combination therapy causes greater mitochondrial damage and apoptosis in K562 cancer cells compared to ultrasound alone.

Area of Science:

  • Oncology
  • Biophysics
  • Biochemistry

Background:

  • Ultrasound therapy is an emerging treatment for malignant cancers.
  • Investigating novel therapeutic combinations is crucial for improving cancer control.

Purpose of the Study:

  • To evaluate the synergistic effect of 5-aminolaevulinic acid (5-ALA) on ultrasound-induced cancer cell death.
  • To explore the underlying mechanisms of combined 5-ALA and ultrasound treatment on cancer cells.

Main Methods:

  • K562 cancer cells were treated with 5-ALA (2mM) and ultrasound (1.7MHz, 0.46 W/cm², 15s).
  • Cytotoxicity was assessed using trypan blue exclusion.
  • Ultrastructural changes, including mitochondrial morphology, were analyzed via transmission electron microscopy (TEM).
  • Mitochondrial membrane potential (ΔPsim) was measured using Rhodamine 123 assay.

Main Results:

  • Combined 5-ALA and ultrasound treatment resulted in a significantly higher K562 cell death rate (46.87%) compared to ultrasound alone (12.61%) or 5-ALA alone (1.27%).
  • TEM revealed increased mitochondrial swelling, vacuolization, and features of apoptosis (nuclear condensation) in cells treated with both agents.
  • Mitochondrial membrane potential (ΔPsim) was more severely collapsed in the combined treatment group.

Conclusions:

  • 5-ALA pretreatment significantly potentiates the cytotoxic effects of ultrasound therapy on K562 cancer cells.
  • Mitochondrial damage and dysfunction are key contributors to cell death induced by combined 5-ALA and ultrasound treatment.